In some embodiments, the otic formulation or composition contains at least one viscosity modulating agent that provides the otic formulation or composition with a viscosity of about 2 cP, about 5 cP, about 10 cP, about 20 cP, about 30 cP, about 40 cP, about 50 cP, about 60 cP, about 70 cP, about 80 cP, about 90 cP, about 100 cP, about 200 cP, about 300 cP, about 400 cP, about 500 cP, about 600 cP, about 700 cP, about 800 cP, about 900 cP, about 1,000 cP, about 5,000 cP, about 10,000 cP, about 20,000 cP, about 50,000 cP, about 100,000 cP, or about 250,000 cP
[DOI] [PMC free article] [PubMed] [Google Scholar] 17.Guijarro-Real C., Fita A., Prohens J., Moreno D.A
Basic Profile of Tirzepatide Drug Information Table 2
But that hasnt happened, and the companys CEO said on its Q2 earnings call that the copycat GLP-1 market is of equal size to Novos business-likely due to the lower cost of compounded drugs
Sea Buckthorn Innovation featuring 190+ bioactive nutrients including Omega-7